Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26919ArticlesСтатьиResearch ArticleBone mineral density in patient with breast cancerМинеральная плотность костей у больных раком молочной железыPoddubnayaI VПоддубнаяИрина Владимировна

чл.-кор. РАМН, д-р мед. наук, проф., зав. каф. онкологии

KizhaevE VКижаевЕвгений Васильевич

д-р мед. наук, проф., зав. каф. радиологии

KolyadinaI VКолядинаИрина Владимировна

канд. мед. наук, ассистент каф. онкологии

BanovS MБановСергей Михайлович

канд. мед. наук, зав. отд-нием клиники ГБОУ ДПО РМАПО

ZhmaevaE MЖмаеваЕлена Михайловна

канд. мед. наук, ассистент каф. радиологии

SeckoM AСецкоМаксим Александрович

аспирант каф. онкологии

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва15122013154VOL 15, NO4 (2013)ТОМ 15, №4 (2013)223009042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26919

Literature review on the results of clinical studies of the condition of bone mineral density (BMD) in patients with breast cancer (BC) is represented. Evidence of significant change in BMD in patients with breast cancer after adjuvant chemotherapy and hormonal treatment are given. Meaning of menopausal status, hormone therapy options on the state of BMD in patients with breast cancer were reflected. Effectiveness of bisphosphonates for the prevention of reduction of BMD in patients with breast cancer was shown. Data on more effective immediate bisphosphonates against delayed administration were presented. Current algorithms bisphosphonates in patients with breast cancer to prevent decline BMD were reflected.

Представлен обзор литературы по результатам клинических исследований состояния минеральной плотности костей (МПК) у больных раком молочной железы (РМЖ). Приведены данные о значительном изменении МПК у больных РМЖ после проведения адъювантной химиотерапии и эндокринотерапии. Отражено значение менструального статуса, вариантов гормонотерапии на состояние МПК у больных РМЖ. Показана эффективность назначения бисфосфонатов для профилактики снижения МПК у больных РМЖ. Представлены данные о большей эффективности немедленного назначения бисфосфонатов против отсроченного назначения. Отражены текущие алгоритмы назначения бисфосфонатов у больных РМЖ для профилактики снижения МПК.

breast cancerbone mineral densitybisphosphonatestamoxifen and aromatase inhibitorszometaрак молочной железыминеральная плотность костейбисфосфонатытамоксифенингибиторы аромата- зызометаПоддубная И.В., Колядина И.В., Трофимова О.П. и др. Прогностическое значение локального и системного лечения при раке молочной железы I стадии. Соврем. онкология. 2013; 3: 33–40.Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early - stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.Baum M, Hackshaw A, Houghton J et al. Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006; 42: 895–904.Body J.J, Bergmann P, Boonen S et al. Management of cancer treatment - induced bone loss in early breast and prostate cancera consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18: 1439–50.Burstein H.J, Prestrud A.A, Seidenfeld J et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor - positive breast cancer. J Clin Oncol 2010; 28: 3784–96.Coleman R.E, Banks L.M, Girgis S.I et al. Skeletal effects of exemestane on bone - mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8: 119–27.Cooke A.L, Metge C, Lix L et al. Tamoxifen use and osteoporotic fracture risk: A population - based analysis. J Clin Oncol 2008; 26: 5227–32.Cummings S.R, Bates D, Black D.M. Clinical use of bone densitometry: Scientific review. JAMA 2002; 288: 1889–97.Cummings S.R, Nevitt M.C, Browner W.S et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73.Cuzick J, Ambroisine L, Davidson N et al. Use of luteinising - hormonereleasing hormone agonists as adjuvant treatment in premenopausal patients with hormone - receptorpositive breast cancer: A meta - analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711–23.David M, Reid A, Doughty J.B et al. Guidance for the management of breast cancer treatment - induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews 2008; 34: s3.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687–717.Eastell R, Adams J.E, Coleman R.E et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole Tamoxifen Alone or in Combination Trial 18233230. J Clin Oncol 2008; 26: 1051–7.Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188–94.Ellis G.K, Bone H.G, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.Faulkner K.G. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183–7.Geisler J, Lonning P.E. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95: 75–81.Gnant M.F, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment - induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone - responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820–8.Good P.J, Ennis M, Pritchard K.I et al. Prognostic effects of 25-hydroxyvitamin D Leveis in early breast cancer. J Clin Oncol 2009; 27: 3757–63.Azim H.A, Azambuja J.E, Colozza M et al. Long - term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncology 2011; 22: 1939– 47.Hillner B.E, Ingle J.N, Chlebowski R.T et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57.Hofbauer L.C, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490–5.Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 year’s adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2009; 59: 225–49.Lester J.E, Dodwell D, Horsman J.M et al. Current management of treatment - induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006; 94: 30–5.Lester J.E, Dodwell D, Purohit O.P et al. Prevention of anastrozole - induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336–42.Lewiecki E.M. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006; 6: 1041–50.Love R.R, Mazess R.B, Barden H.S et al. Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6.Marshall D, Johnell O, Wedel H. Meta - analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9.National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htmPacifici R. Estrogen cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.Park-Wyllie L, Mamdani M, Juurlink D et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–9.Perez E.A, Josse R.G, Pritchard K.I et al. Effect of letrozole vs placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. J Clin Oncol 2006; 24: 3629–35.Plevritis S.K, Fryback D.G, Clarke L et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784–92.Powles T.J, Hickish T, Kanis J.A et al. Effect of tamoxifen on bone mineral density measured by dual - energy x - ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84.Russell R.G, Watts N.B, Ebetino F.H, Rogers M.J. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733–59.Simpson E.R, Dowsett M. Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 2002; 57: 317–38.Syed Z, Khan A. Bone densitometry: Applications and limitations. J Obstet Gynaecol Can 2002; 24: 476–84.Thurlimann B, Keshaviah A, Coates A.S et al. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.Valachis A, Polyzos N.P, Georgoulias V et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta - analysis. Gynecol Oncol 2010; 117: 139–45.Van Poznak C, Hannon R.A, Mackey J.R et al. Prevention of aromatase inhibitor - induced bone loss using risedronate: The SABRE trial. J Clin Oncol 2010; 28: 967–75.Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24 (4): 675–80.Warne G.T, Failey K.F, Hobbs J.B, Martin F.I. Cyclophosphamide - induced ovarian failure. N Engl J Med 1973; 289: 1159–62.Warne G.T, Failey K.F, Hobbs J.B, Martin F.I. Cyclophosphamide - induced ovarian failure. N Engl J Med 1973; 289: 1159–62.Weitzmann M.N, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006; 116: 1186–94.